Drug Trial Radar · NCT07246525
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4,800
Planned (sponsor's estimate)
Start
Sep 22, 2026
Primary completion
Nov 15, 2029
Study completion Nov 15, 2029
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Infectious Diseases Research Collaboration, Uganda; Ministry of Health, Uganda
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the study hypothesis is that IPTsc will reduce this infectious reservoir and thus the burden of malaria in persons of all ages in surrounding communities.
Conditions
- Malaria
Interventions
dihydroartemisinin-piperaquineDrug
D-Artepp, is manufactured by Guilin Pharmaceutical Co Ltd, and is prequalified by the WHO and approved for use in Uganda by the National Drug Authority. Standard treatment doses of DP (once a day x 3 days) will be administered using weight-based guidelines targeting a total dose of 6.4 mg/kg dihydroartemisinin and 51.2 mg/kg of piperaquine as per manufacturer's instructions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of cases of laboratory-confirmed malaria diagnosed among patients residing in the target area during the period the intervention is implementedTime frame: 24 months after intervention implemented
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Infectious Diseases Research Collaboration
Kampala, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.